THE two former senior executives at the drug company Elan received almost $2 million (€1.68m) in payments last year even though they resigned as directors almost two years ago.

DURING 14 years of hard graft with Elan Donal Geaney played a key role in transforming it from a 32-person concern into a 24.5 billion international pharmaceutical company.